Loading…

Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs

Despite the success of TNF-alpha inhibitor (TNFi) treatment in rheumatoid arthritis (RA), a substantial number of patients necessitate discontinuation. Prediction thereof would be clinically relevant and guide the decision whether to start TNFi treatment. Data were used from the observational BiOCUR...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2017-03, Vol.35 (2), p.221-228
Main Authors: Cuppen, Bart V J, Jacobs, Johannes W G, Ter Borg, Evert-Jan, Marijnissen, Anne C A, Bijlsma, Johannes W J, Lafeber, Floris P J G, van Laar, Jacob M
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the success of TNF-alpha inhibitor (TNFi) treatment in rheumatoid arthritis (RA), a substantial number of patients necessitate discontinuation. Prediction thereof would be clinically relevant and guide the decision whether to start TNFi treatment. Data were used from the observational BiOCURA cohort, in which patients initiating biological treatment were enrolled and followed up for one year. In the model development cohort (n=192), a model predicting TNFi discontinuation was built using Cox-regression with backward selection (p
ISSN:0392-856X